Search
Teclistamab
go.drugbank.com/drugs/DB16655ApprovedInvestigationalcells to promote T cell–mediated cytotoxicity. … Teclistamab is an IgG4-PAA bispecific antibody that targets the CD3 receptor expressed on the surface of T cells and B cell maturation antigen (BCMA) expressed on malignant multiple myeloma cells.
Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerTirofiban
go.drugbank.com/drugs/DB00775ApprovedInvestigationalTirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. … It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
Synonyms: (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid, N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosineProducts: INFÜZYON IÇIN KONSANTRE ÇÖZELTI IÇEREN FLAKON ,1 ADET, TIROSTU 12.5 MG/50 ML IV KONSANTRE İNFÜZYONLUK ÇÖZELTİ, 1 ADETLebrikizumab
go.drugbank.com/drugs/DB11914ApprovedInvestigationalLebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity and slow off-rate.[L51374] It binds to a different epitope compared [tralokinumab]. … This approval is based on the positive results obtained from the Phase 3 studies ADvocate 1 and ADvocate 2, where nearly 80% of patients taking lebrikizumab either as monotherapy or combination therapy
Relatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41265,L41300] It was the first anti-LAG-3 antibody to demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval. … [L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001]
Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: Lymphocyte Activation Gene-3 BlockerSomatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigationalIt is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and … growth hormone caused by growth hormone deficiency, marking Canada as the first country to approve this drug.
Synonyms: HUMAN GROWTH HORMONE-CARBOXY-TERMINAL PEPTIDE (CTP) OF THE BETA CHAIN OF HUMAN CHORIONIC GONADOTROPIN FUSION PROTEIN, Recombinant human growth hormone long acting (fused w beta chains of HCG)Products: NGENLA 24 MG/1,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET, NGENLA 60 MG/1,2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADETTedizolid
go.drugbank.com/drugs/DB14569ApprovedInvestigational[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive … [L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®).
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Heterocyclic Compounds, 1-RingOritavancin
go.drugbank.com/drugs/DB04911ApprovedInvestigationalIt boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy. … Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis).
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2C19 InhibitorsColesevelam
go.drugbank.com/drugs/DB00930ApprovedInvestigationalColesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. … It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in the body. Removing these bile acids helps to lower blood cholesterol.
Perboric acid
go.drugbank.com/drugs/DB13235Approved[F66] Perboric acid in the form of sodium perborate is approved by Health Canada since 2004 to be used as a disinfectant of medical instruments. … [L1113] By the FDA, sodium perborate is approved as an ointment for the protection of poison ivy dermatitis.[L2764]
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedAs patients with haemophilia A are predisposed to episodes of recurrent bleeding [L1115], simoctocog alfa can be administered for the treatment or prevention of bleeding such as prior to surgical procedures … It is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system.